CALCR, RAMP1: Amylin receptor AMY1, CALCR/RAMP1
Complex in Homo sapiens that 2 drugs act on.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CALCR, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 2
| PramlintideBoxed warning | Approved | AstraZeneca Pharmaceuticals | Protein or peptide | AgonistAmylin receptor AMY1, CALCR/RAMP1 agonist | 6 |
| Davalintide | Phase 2 | AstraZeneca Pharmaceuticals | Protein or peptide | AgonistAmylin receptor AMY1, CALCR/RAMP1 agonist | 0 |
| Outpatient Pramlintide Study | Pramlintide | Not applicable | Not yet recruiting | Oregon Health and Science University | Nov 3, 2026 |
| Postprandial Regulation of Bone Perfusion in Healthy Individuals | Pramlintide | Not applicable | Not yet recruiting | University of Copenhagen | Jul 1, 2026 |
| Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans | Pramlintide | Not applicable | Recruiting | University Hospital, Gentofte, Copenhagen | Apr 1, 2026 |
| Hypersensitivity to Amylin in Post-Traumatic Headache | Pramlintide | Not applicable | Recruiting | Danish Headache Center | Jan 14, 2026 |
| Amylin-Induced Migraine Attacks Without Aura | Pramlintide | Not applicable | Not yet recruiting | Danish Headache Center | Jan 14, 2026 |
| Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease | Pramlintide | Early phase 1 | Active, not recruiting | Boston University | Jun 19, 2018 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2111189, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets